OptimizeRx Corp Quarterly Cost of Revenue in USD from Q3 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
OptimizeRx Corp quarterly/annual Cost of Revenue history and growth rate from Q3 2013 to Q2 2024.
  • OptimizeRx Corp Cost of Revenue for the quarter ending June 30, 2024 was $7.11M, a 18.6% increase year-over-year.
  • OptimizeRx Corp Cost of Revenue for the twelve months ending June 30, 2024 was $31.7M, a 29.6% increase year-over-year.
  • OptimizeRx Corp annual Cost of Revenue for 2023 was $28.6M, a 21.9% increase from 2022.
  • OptimizeRx Corp annual Cost of Revenue for 2022 was $23.5M, a 8.46% decline from 2021.
  • OptimizeRx Corp annual Cost of Revenue for 2021 was $25.7M, a 33.6% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $31.7M $7.11M +$1.12M +18.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-15
Q1 2024 $30.5M $7.49M +$1.92M +34.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $28.6M $10.5M +$3.33M +46.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 $25.3M $6.53M +$866K +15.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $24.4M $5.99M +$1M +20.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-15
Q1 2023 $23.4M $5.57M -$59.9K -1.06% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $23.5M $7.2M -$721K -9.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 $24.2M $5.66M -$1.38M -19.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $25.6M $4.99M -$592K -10.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $26.2M $5.63M +$525K +10.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $25.7M $7.92M +$98.7K +1.26% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-10
Q3 2021 $25.6M $7.05M +$2.54M +56.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $23M $5.58M +$1.94M +53.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $21.1M $5.1M +$1.86M +57.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $19.2M $7.82M +$4.92M +169% Oct 1, 2020 Dec 31, 2020 10-K/A 2023-03-10
Q3 2020 $14.3M $4.5M +$2.52M +127% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $11.8M $3.64M +$952K +35.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $10.8M $3.24M +$1.66M +105% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $9.16M $2.91M +$421K +16.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 $8.74M $1.98M -$288K -12.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $9.03M $2.69M +$450K +20.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $8.58M $1.58M -$425K -21.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $9M $2.49M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 $2.27M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $2.24M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $2.01M +$626K +45.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q1 2017 $1.38M +$489K +54.8% Jan 1, 2017 Mar 31, 2017 10-Q 2017-05-03
Q1 2016 $893K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-03
Q3 2014 $859K +$330K +62.3% Jul 1, 2014 Sep 30, 2014 10-Q 2014-11-13
Q3 2013 $529K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.